Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study
Achieving HCV elimination in China by 2030 will require significant investment in large-scale universal screening and treatment, but it will yield substantial health and economic benefits and is cost-effective.
Authors
- Aaron G. Lim (ORCID: https://orcid.org/0000-0002-3141-7496)
- Sini Li (ORCID: https://orcid.org/0000-0002-1347-4024)
- Xuehong Wang (ORCID: https://orcid.org/0000-0001-7251-9643)
- Mei-Yu Wu (ORCID: https://orcid.org/0009-0005-4991-4422)
- Ouyang Xie
- Jing Ma (ORCID: https://orcid.org/0000-0001-9082-4844)
- Chongqing Tan (ORCID: https://orcid.org/0000-0002-6007-4170)
- Andong Li (ORCID: https://orcid.org/0000-0001-5291-2720)
- Xiaomin Wan
Institutions
- Central South University (CN)
- Chinese University of Hong Kong (HK)
- University of Bristol (GB)
- Second Xiangya Hospital of Central South University (CN)
Publication Details
- Journal
- Clinical and Molecular Hepatology
- Published
- 2024-12-03
- DOI
- https://doi.org/10.3350/cmh.2024.0664
- Citations
- 5
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 1.85
Funders
- National Natural Science Foundation of China